Bioequivalence Study of Fluvastatin Sodium Extended Release Tablets in Healthy Participants
Status:
NOT_YET_RECRUITING
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the bioequivalence of the test preparation (Fluvastatin sodium extended release tablet, 80 mg) manufactured by Shenzhen Salubris Pharmaceuticals Co., Ltd. and the reference preparation (80 mg) manufactured by Beijing Novartis Pharma Co., Ltd. in healthy participants under fasting and fed conditions.